Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans

Journal of Ocular Pharmacology and Therapeutics

Volumn 25, Issue 4, 2009, Pages 335-343

  Proksch, Joel W ^a   Granvil, Camille P ^b   Siou Mermet, Raphaële ^c   Comstock, Timothy L ^a   Paterno, Michael R ^a   Ward, Keith W ^a  

^a Bausch and Lomb   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c BAUSCH AND LOMB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BESIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG PENETRATION; DRUG TISSUE LEVEL; FEMALE; HAEMOPHILUS INFLUENZAE; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORMAL HUMAN; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE;

ADMINISTRATION, TOPICAL; ADULT; ANIMALS; ANTI-BACTERIAL AGENTS; AQUEOUS HUMOR; AREA UNDER CURVE; AZEPINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CONJUNCTIVA; CORNEA; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROQUINOLONES; HALF-LIFE; HUMANS; MACACA FASCICULARIS; MALE; MICROBIAL SENSITIVITY TESTS; OPHTHALMIC SOLUTIONS; RABBITS; SPECIES SPECIFICITY; TANDEM MASS SPECTROMETRY; TEARS; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 68549092580     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2008.0116     Document Type: Article

References (32)

1. Mah, F.S. Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infections. Curr. Opin. Ophthalmol. 15:316-320, 2004.
2. Thielen, T.L., Castle, S.S., and Terry, J.E. Anterior ocular infections: an overview of pathophysiology and treatment. Ann. Pharmacother. 34:235-246, 2000. (Pubitemid 30082982)
3. Kurokawa, N., Hayashi, K., Konishi, M., et al. Increasing ofloxacin resistance of bacterial flora from conjunctival sac of preoperative ophthalmic patients in Japan. Jpn. J. Ophthalmol. 46:586-589, 2002. (Pubitemid 35380016)
4. Yamada, M., Yoshida, J., Hatou, S., et al. Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones. Br. J. Ophthalmol. 92:848-851, 2008. (Pubitemid 351839582)
5. Afshari, N.A., Ma, J.J., Duncan, S.M., et al. Trends in resistance to ciprofloxacin, cefazolin, and gentamicin in the treatment of bacterial keratitis. J. Ocul. Pharmacol. Ther. 24:217-223, 2008.
6. Robert, P.Y., and Adenis, J.P. Comparative review of topical ophthalmic antibacterial preparations. Drugs. 61:175-185, 2001.
7. Holland, E.J., Lane, S.S., Kim, T., et al. Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty. Cornea.27:314-319, 2008.
8. Robertson, S.M., Curtis, M.A., Schlech, B.A., et al. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. Surv. Ophthalmol. 50(Suppl 1):S32-S45, 2005. (Pubitemid 41657597)
9. Wagner, R.S., Abelson, M.B., Shapiro, A., et al. Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levo- floxacin concentrations in human conjunctival tissue. Arch. Ophthalmol. 123:1282-1283, 2005. (Pubitemid 41316756)
10. Donnenfeld, E.D., Perry, H.D., Snyder, R.W., et al. Intracorneal, aqueous humor, and vitreous humor penetration of topical and oral ofloxacin. Arch. Ophthalmol. 115:173-176, 1997. (Pubitemid 27083787)
11. Hariprasad, S.M., Blinder, K.J., Shah, G.K., et al. Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous. Arch. Ophthalmol. 123:39-44, 2005. (Pubitemid 40105427)
12. Raizman, M.B., Rubin, J.M., Graves, A.L., et al. Tear concentrations of levofloxacin following topical administration of a single dose of 0.5% levofloxacin ophthalmic solution in healthy volunteers. Clin. Ther. 24:1439-1450, 2002.
13. Chiambaretta, F., Garraffo, R., Elena, P.P., et al. Tear concentrations of azithromycin following topical administration of a single dose of azithromycin 0.5%, 1.0%, and 1.5% eyedrops (T1225) in healthy volunteers. Eur. J. Ophthalmol. 18:13-20, 2008.
14. Richman, J., Zolezio, H., and Tang-Liu, D. Comparison of ofloxacin, gentamicin, and tobramycin concentrations in tears and in vitro MICs for 90% of test organisms. Antimicrob. Agents Chemother. 34:1602-1604, 1990. (Pubitemid 20257618)
15. Ward, K.W., Lepage, J.F., and Driot, J.Y. Nonclinical pharmacodynamics, pharmacokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use. J. Ocul. Pharmacol. Ther. 23:243-256, 2007.
16. Arnold, D.R., Granvil, C.P., Ward, K.W., et al. Quantitative determination of besifloxacin, a novel fluoroquinolone antimicrobial agent, in human tears by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 867:105-110, 2008.
17. Gabrielson, J., and Weiner, D. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. 3rd ed. Stockholm, Sweden: Apotekarsocieteten; 2000.
18. Holland, E.J., McCarthy, M., and Holland, S. The ocular penetration of levofloxacin 1.5% and gatifloxacin 0.3% ophthalmic solutions in subjects undergoing corneal transplant surgery. Curr. Med. Res. Opin. 23:2955-2960, 2007.
19. Lee, V.H., and Robinson, J.R. Topical ocular drug delivery: recent developments and future challenges. J. Ocul. Pharmacol. 2:67-108, 1986.
20. Acheampong, A.A., Shackleton, M., John, B., et al. Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes. Drug Metab. Dispos. 30:421-429, 2002. (Pubitemid 34263827)
21. Tai, M.C., Lu, D.W., and Chiang, C.H. Corneal and scleral permeability of quinolones-a pharmacokinetics study. J. Ocul. Pharmacol. Ther. 19:547-554, 2003.
22. Levine, J.M., Noecker, R.J., Lane, L.C., et al. Comparative penetration of moxifloxacin and gatifloxacin in rabbit aqueous humor after topical dosing. J. Cataract. Refract. Surg. 30:2177-2182, 2004. (Pubitemid 39330678)
23. Mishima, S. Clinical pharmacokinetics of the eye. Proctor lecture. Invest. Ophthalmol. Vis. Sci. 21:504-541, 1981. (Pubitemid 11031057)
24. Akkan, A.G., Mutlu, I., Ozyazgan, S., et al. Comparative tear concentrations of topically applied ciprofloxacin, ofloxacin, and norfloxacin in human eyes. Int. J. Clin. Pharmacol. Ther. 35:214-217, 1997. (Pubitemid 27229463)
25. Wright, D.H., Brown, G.H., Peterson, M.L., et al. Application of fluoroquinolone pharmacodynamics. J. Antimicrob. Chemother. 46:669-683, 2000.
26. Hyatt, J.M., McKinnon, P.S., Zimmer, G.S., et al. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin. Pharmacokinet. 28:143-160, 1995.
27. Allen, G.P., Kaatz, G.W., and Rybak, M.J. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model. Int. J. Antimicrob. Agents. 24:150-160, 2004. (Pubitemid 38993694)
28. Metzler, K., Hansen, G.M., Hedlin, P., et al. Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus. Int. J. Antimicrob. Agents. 24:161-167, 2004. (Pubitemid 38993695)
29. Nightingale, C.H. Future in vitro and animal studies: development of pharmacokinetic and pharmacodynamic efficacy predictors for tissue-based antibiotics. Pharmacotherapy. 25:146S-149S, 2005.
30. Wilhelmus, K.R. Evaluation and prediction of fluoroquinolone pharmacodynamics in bacterial keratitis. J. Ocul. Pharmacol. Ther. 19:493-499, 2003.
31. Madaras-Kelly, K.J., Ostergaard, B.E., Hovde, L.B., et al. Twentyfour- hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 40:627-632, 1996. (Pubitemid 26071528)
32. Ambrose, P.G., Bhavnani, S.M., and Owens, R.C., Jr. Clinical pharmacodynamics of quinolones. Infect. Dis. Clin. North Am. 17:529-543, 2003.